About BreezeBio
Genetic Medicine Delivered
- Industry
- Biotechnology Research
- Company size
- 51-200 employees
- Headquarters
- Brisbane, California
- Company type
- Privately Held
BreezeBio is a biotechnology company developing precision genetic medicines enabled by targeted, non-viral delivery across biologically relevant tissues. Using our proprietary NanoGalaxy® platform, we engineer nanoparticles designed to deliver genetic payloads, including mRNA, to specific cell types. Our platform has demonstrated delivery to immune cells as well as select tissues in the heart, lung, and central nervous system. We are advancing an internal therapeutic pipeline focused on autoimmune diseases and oncology. Our lead program, BRZ-101, is designed to restore immune tolerance in type 1 diabetes and is advancing into IND-enabling studies. BreezeBio is headquartered in the South San Francisco area.
Company locations
3000 Marina Blvd, 350, Brisbane, California 94005, US
Locations listed on the company profile. These may include offices outside the United States, and not every location is hiring.
Business areas
- Health Care
- Biopharma
- Nanotechnology
- Biotechnology
- Genetics
- Artificial Intelligence (AI)
- Pharmaceutical
- Therapeutics
On LinkedIn
- Followers
- 4,528
- People linked to this company
- 66
People who list this company on LinkedIn, not a verified employee count. Figures reflect the saved company profile.
Funding raised
127,725,000 USD
Total reported by Crunchbase, in US dollars. This is funding raised, not company revenue or valuation.
Explore the company
Employer category
Other employer
Estimated from the company profile. This category has not been confirmed by the employer.